North America and Europe Alzheimer’s Disease Drug Market by Manufacturers, Regions, Type and Application, Forecast to 2023
Alzheimer's disease (AD), also referred to simply as Alzheimer's, is a chronic neurodegenerative disease that usually starts slowly and worsens over time. It is the cause of 60% to 70% of cases of dementia.
Scope of the Report:
This report focuses on the Alzheimer’s Disease Drug in North America and Europe market, especially in United States, United Kingdom, Canada, Germany, France, Italy and Spain. This report categorizes the market based on manufacturers, countries/Regions, type and application.
Market Segment by Manufacturers, this report covers
Chapter 1, to describe Alzheimer’s Disease Drug Introduction, product type and application, market overview, market analysis by countries, market opportunities, market risk, market driving force;
Chapter 2, to analyze the manufacturers of Alzheimer’s Disease Drug, with profile, main business, news, sales, price, revenue and market share in 2016 and 2017;
Chapter 3, to display the competitive situation among the top manufacturers, with sales, revenue and market share in 2016 and 2017;
Chapter 4, to show the North America and Europe market by countries, covering United States, United Kingdom, Canada, France, Germany, Italy and Spain, with sales, price, revenue and market share of Alzheimer’s Disease Drug, for each country, from 2013 to 2018;
Chapter 5 and 6, to show the market by type and application, with sales, price, revenue, market share and growth rate by type, application, from 2013 to 2018;
Chapter 7, 8, 9, 10, 11, 12 and 13 to analyze the key countries by manufacturers, Type and Application, covering 7 countries, with sales, revenue and market share by manufacturers, types and applications;
Chapter 14, Alzheimer’s Disease Drug market forecast, by countries, type and application, with sales, price, revenue and growth rate forecast, from 2018 to 2023;
Chapter 15, to analyze the manufacturing cost, key raw materials and manufacturing process, etc.
Chapter 16, to analyze the industrial chain, sourcing strategy and downstream end users (buyers);
Chapter 17, to describe sales channel, distributors, traders, dealers, etc.
Chapter 18 and 19, to describe the research findings and conclusion, appendix, methodology and data source.
Scope of the Report:
This report focuses on the Alzheimer’s Disease Drug in North America and Europe market, especially in United States, United Kingdom, Canada, Germany, France, Italy and Spain. This report categorizes the market based on manufacturers, countries/Regions, type and application.
Market Segment by Manufacturers, this report covers
- Allergan
- Eisai
- Novartis
- Daiichi Sankyo
- Merz Pharma
- Pfizer
- Johnson & Johnson
- Lundbeck.
- United States
- United Kingdom
- Canada
- Germany
- France
- Italy
- Spain
- Donepezil
- Memantine
- Rivastigmine
- Early to Moderate Stages
- Moderate to Severe Stages
Chapter 1, to describe Alzheimer’s Disease Drug Introduction, product type and application, market overview, market analysis by countries, market opportunities, market risk, market driving force;
Chapter 2, to analyze the manufacturers of Alzheimer’s Disease Drug, with profile, main business, news, sales, price, revenue and market share in 2016 and 2017;
Chapter 3, to display the competitive situation among the top manufacturers, with sales, revenue and market share in 2016 and 2017;
Chapter 4, to show the North America and Europe market by countries, covering United States, United Kingdom, Canada, France, Germany, Italy and Spain, with sales, price, revenue and market share of Alzheimer’s Disease Drug, for each country, from 2013 to 2018;
Chapter 5 and 6, to show the market by type and application, with sales, price, revenue, market share and growth rate by type, application, from 2013 to 2018;
Chapter 7, 8, 9, 10, 11, 12 and 13 to analyze the key countries by manufacturers, Type and Application, covering 7 countries, with sales, revenue and market share by manufacturers, types and applications;
Chapter 14, Alzheimer’s Disease Drug market forecast, by countries, type and application, with sales, price, revenue and growth rate forecast, from 2018 to 2023;
Chapter 15, to analyze the manufacturing cost, key raw materials and manufacturing process, etc.
Chapter 16, to analyze the industrial chain, sourcing strategy and downstream end users (buyers);
Chapter 17, to describe sales channel, distributors, traders, dealers, etc.
Chapter 18 and 19, to describe the research findings and conclusion, appendix, methodology and data source.
1 MARKET OVERVIEW
1.1 Alzheimer’s Disease Drug Introduction
1.2 Market Analysis by Type
1.2.1 Donepezil
1.2.2 Memantine
1.2.3 Rivastigmine
1.3 Market Analysis by Applications
1.3.1 Early to Moderate Stages
1.3.2 Moderate to Severe Stages
1.4 Market Analysis by Countries
1.4.1 United States Status and Prospect (2013-2023)
1.4.2 Canada Status and Prospect (2013-2023)
1.4.3 United Kingdom Status and Prospect (2013-2023)
1.4.4 Germany Status and Prospect (2013-2023)
1.4.5 France Status and Prospect (2013-2023)
1.4.6 Italy Status and Prospect (2013-2023)
1.4.7 Spain Status and Prospect (2013-2023)
1.5 Market Dynamics
1.5.1 Market Opportunities
1.5.2 Market Risk
1.5.3 Market Driving Force
2 MANUFACTURERS PROFILES
2.1 Allergan
2.1.1 Business Overview
2.1.2 Alzheimer’s Disease Drug Type and Applications
2.1.2.1 Type
2.1.2.2 Type
2.1.3 Allergan Alzheimer’s Disease Drug Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.2 Eisai
2.2.1 Business Overview
2.2.2 Alzheimer’s Disease Drug Type and Applications
2.2.2.1 Type
2.2.2.2 Type
2.2.3 Eisai Alzheimer’s Disease Drug Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.3 Novartis
2.3.1 Business Overview
2.3.2 Alzheimer’s Disease Drug Type and Applications
2.3.2.1 Type
2.3.2.2 Type
2.3.3 Novartis Alzheimer’s Disease Drug Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.4 Daiichi Sankyo
2.4.1 Business Overview
2.4.2 Alzheimer’s Disease Drug Type and Applications
2.4.2.1 Type
2.4.2.2 Type
2.4.3 Daiichi Sankyo Alzheimer’s Disease Drug Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.5 Merz Pharma
2.5.1 Business Overview
2.5.2 Alzheimer’s Disease Drug Type and Applications
2.5.2.1 Type
2.5.2.2 Type
2.5.3 Merz Pharma Alzheimer’s Disease Drug Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.6 Pfizer
2.6.1 Business Overview
2.6.2 Alzheimer’s Disease Drug Type and Applications
2.6.2.1 Type
2.6.2.2 Type
2.6.3 Pfizer Alzheimer’s Disease Drug Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.7 Johnson & Johnson
2.7.1 Business Overview
2.7.2 Alzheimer’s Disease Drug Type and Applications
2.7.2.1 Type
2.7.2.2 Type
2.7.3 Johnson & Johnson Alzheimer’s Disease Drug Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.8 Lundbeck.
2.8.1 Business Overview
2.8.2 Alzheimer’s Disease Drug Type and Applications
2.8.2.1 Type
2.8.2.2 Type
2.8.3 Lundbeck. Alzheimer’s Disease Drug Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
3 NORTH AMERICA AND EUROPE ALZHEIMER’S DISEASE DRUG MARKET COMPETITION, BY MANUFACTURER
3.1 North America and Europe Alzheimer’s Disease Drug Sales and Market Share by Manufacturer (2016-2017)
3.2 North America and Europe Alzheimer’s Disease Drug Revenue and Market Share by Manufacturer (2016-2017)
3.2.1 North America and Europe Alzheimer’s Disease Drug Revenue by Manufacturer (2016-2017)
3.2.2 North America and Europe Alzheimer’s Disease Drug Revenue Market Share by Manufacturer (2016-2017)
3.3 North America and Europe Alzheimer’s Disease Drug Price by Manufacturers (2016-2017)
3.4 Market Concentration Rate
3.4.1 Top 3 Alzheimer’s Disease Drug Manufacturer Market Share (2016-2017)
3.4.2 Top 5 Alzheimer’s Disease Drug Manufacturer Market Share (2016-2017)
3.5 Market Competition Trend
4 NORTH AMERICA AND EUROPE ALZHEIMER’S DISEASE DRUG MARKET ANALYSIS BY COUNTRIES/REGIONS
4.1 North America and Europe Alzheimer’s Disease Drug Sales Market Share by Countries/Regions
4.2 North America and Europe Alzheimer’s Disease Drug Sales by Countries/Regions (2013-2018)
4.2.1 North America and Europe Alzheimer’s Disease Drug Sales by Countries/Regions (2013-2018)
4.2.2 North America and Europe Alzheimer’s Disease Drug Sales Market Share by Countries (2013-2018)
4.3 North America and Europe Alzheimer’s Disease Drug Revenue (Value) by Countries (2013-2018)
4.3.1 North America and Europe Alzheimer’s Disease Drug Revenue and Growth Rate (2013-2018)
4.3.2 North America and Europe Alzheimer’s Disease Drug Revenue Market Share by Countries (2013-2018)
5 NORTH AMERICA AND EUROPE MARKET SEGMENTATION ALZHEIMER’S DISEASE DRUG BY TYPE
5.1 North America and Europe Alzheimer’s Disease Drug Sales, Revenue and Market Share by Type (2013-2018)
5.1.1 North America and Europe Alzheimer’s Disease Drug Sales and Market Share by Type (2013-2018)
5.1.2 North America and Europe Alzheimer’s Disease Drug Revenue and Market Share by Type (2013-2018)
5.2 Donepezil Sales Growth and Price
5.2.1 North America and Europe Donepezil Sales Growth (2013-2018)
5.2.2 North America and Europe Donepezil Price (2013-2018)
5.3 Memantine Sales Growth and Price
5.3.1 North America and Europe Memantine Sales Growth (2013-2018)
5.3.2 North America and Europe Memantine Price (2013-2018)
5.4 Rivastigmine Sales Growth and Price
5.4.1 North America and Europe Rivastigmine Sales Growth (2013-2018)
6 NORTH AMERICA AND EUROPE MARKET SEGMENTATION ALZHEIMER’S DISEASE DRUG BY APPLICATION
6.1 North America and Europe Alzheimer’s Disease Drug Sales Market Share by Application (2013-2018)
6.2 Early to Moderate Stages Sales Growth (2013-2018)
6.3 Moderate to Severe Stages Sales Growth (2013-2018)
7 UNITED STATES ALZHEIMER’S DISEASE DRUG SALES, REVENUE, BY TYPE, APPLICATION AND MANUFACTURERS
7.1 United States Alzheimer’s Disease Drug Revenue, Sales and Growth Rate (2013-2018)
7.2 United States Alzheimer’s Disease Drug Sales and Market Share by Type (2013-2018)
7.2.1 United States Alzheimer’s Disease Drug Sales by Type (2013-2018)
7.2.2 United States Alzheimer’s Disease Drug Sales Market Share by Type (2013-2018)
7.3 United States Alzheimer’s Disease Drug Sales and Market Share by Application (2013-2018)
7.3.1 United States Alzheimer’s Disease Drug Sales by Application (2013-2018)
7.3.2 United States Alzheimer’s Disease Drug Sales Market Share by Application (2013-2018)
7.4 United States Alzheimer’s Disease Drug Sales, Revenue and Market Share by Manufacturer (2016-2017)
7.4.1 United States Alzheimer’s Disease Drug Sales and Market Share by Manufacturer (2016-2017)
7.4.2 United States Alzheimer’s Disease Drug Revenue and Market Share by Manufacturer (2016-2017)
7.5 United States Alzheimer’s Disease Drug Export and Import (2013-2018)
8 UNITED KINGDOM ALZHEIMER’S DISEASE DRUG SALES, REVENUE, BY TYPE, APPLICATION AND MANUFACTURERS
8.1 United Kingdom Alzheimer’s Disease Drug Revenue, Sales and Growth Rate (2013-2018)
8.2 United Kingdom Alzheimer’s Disease Drug Sales and Market Share by Type (2016-2017)
8.2.1 United Kingdom Alzheimer’s Disease Drug Sales by Type (2013-2018)
8.2.2 United Kingdom Alzheimer’s Disease Drug Sales Market Share by Type (2013-2018)
8.3 United Kingdom Alzheimer’s Disease Drug Sales and Market Share by Application (2013-2018)
8.3.1 United Kingdom Alzheimer’s Disease Drug Sales by Application (2013-2018)
8.3.2 United Kingdom Alzheimer’s Disease Drug Sales Market Share by Application (2013-2018)
8.4 United Kingdom Alzheimer’s Disease Drug Sales, Revenue and Market Share by Manufacturer (2016-2017)
8.4.1 United Kingdom Alzheimer’s Disease Drug Sales and Market Share by Manufacturer (2016-2017)
8.4.2 United Kingdom Alzheimer’s Disease Drug Revenue and Market Share by Manufacturer (2016-2017)
8.5 United Kingdom Alzheimer’s Disease Drug Export and Import (2013-2018)
9 CANADA ALZHEIMER’S DISEASE DRUG SALES, REVENUE, BY TYPE, APPLICATION AND MANUFACTURERS
9.1 Canada Alzheimer’s Disease Drug Revenue, Sales and Growth Rate (2013-2018)
9.2 Canada Alzheimer’s Disease Drug Sales and Market Share by Type (2013-2018)
9.2.1 Canada Alzheimer’s Disease Drug Sales by Type (2013-2018)
9.2.2 Canada Alzheimer’s Disease Drug Sales Market Share by Type (2013-2018)
9.3 Canada "&Sheet1!$B$1&" Sales and Market Share by Application (2013-2018)"
9.3.1 Canada Alzheimer’s Disease Drug Sales by Application (2013-2018)
9.3.2 Canada Alzheimer’s Disease Drug Sales Market Share by Application (2013-2018)
9.4 Canada Alzheimer’s Disease Drug Sales, Revenue and Market Share by Manufacturer (2016-2017)
9.4.1 Canada Alzheimer’s Disease Drug Sales and Market Share by Manufacturer (2016-2017)
9.4.2 Canada Alzheimer’s Disease Drug Revenue and Market Share by Manufacturer (2016-2017)
9.5 Canada Alzheimer’s Disease Drug Export and Import (2013-2018)
10 GERMANY ALZHEIMER’S DISEASE DRUG SALES, REVENUE, BY TYPE, APPLICATION AND MANUFACTURERS
10.1 Germany Alzheimer’s Disease Drug Revenue, Sales and Growth Rate (2013-2018)
10.2 Germany Alzheimer’s Disease Drug Sales and Market Share by Type (2013-2018)
10.2.1 Germany Alzheimer’s Disease Drug Sales by Type (2013-2018)
10.2.2 Germany Alzheimer’s Disease Drug Sales Market Share by Type (2013-2018)
10.3 Germany Alzheimer’s Disease Drug Sales and Market Share by Application (2013-2018)
10.3.1 Germany Alzheimer’s Disease Drug Sales by Application (2013-2018)
10.3.2 Germany Alzheimer’s Disease Drug Sales Market Share by Application (2013-2018)
10.4 Germany Alzheimer’s Disease Drug Sales, Revenue and Market Share by Manufacturer (2016-2017)
10.4.1 Germany Alzheimer’s Disease Drug Sales and Market Share by Manufacturer (2016-2017)
10.4.2 Germany Alzheimer’s Disease Drug Revenue and Market Share by Manufacturer (2016-2017)
10.5 Germany Alzheimer’s Disease Drug Export and Import (2013-2018)
11 FRANCE ALZHEIMER’S DISEASE DRUG SALES, REVENUE, BY TYPE, APPLICATION AND MANUFACTURERS
11.1 France Alzheimer’s Disease Drug Revenue, Sales and Growth Rate (2013-2018)
11.2 France Alzheimer’s Disease Drug Sales and Market Share by Type (2013-2018)
11.2.1 France Alzheimer’s Disease Drug Sales by Type (2013-2018)
11.2.2 France Alzheimer’s Disease Drug Sales Market Share by Type (2013-2018)
11.3 France "&Sheet1!$B$1&" Sales by Application (2013-2018)"
11.3.1 France Alzheimer’s Disease Drug Sales by Application (2013-2018)
11.3.2 France Alzheimer’s Disease Drug Sales Market Share by Application (2013-2018)
11.4 France Alzheimer’s Disease Drug Sales, Revenue and Market Share by Manufacturer (2016-2017)
11.4.1 France Alzheimer’s Disease Drug Sales and Market Share by Manufacturer (2016-2017)
11.4.2 France Alzheimer’s Disease Drug Revenue and Market Share by Manufacturer
11.5 France Alzheimer’s Disease Drug Export and Import (2013-2018)
12 ITALY ALZHEIMER’S DISEASE DRUG SALES, REVENUE, BY TYPE, APPLICATION AND MANUFACTURERS
12.1 Italy Alzheimer’s Disease Drug Revenue, Sales and Growth Rate (2013-2018)
12.2 Italy Alzheimer’s Disease Drug Sales and Market Share by Type (2013-2018)
12.2.1 Italy Alzheimer’s Disease Drug Sales by Type (2013-2018)
12.2.2 Italy Alzheimer’s Disease Drug Sales Market Share by Type (2013-2018)
12.3 Italy Alzheimer’s Disease Drug Sales and Market Share by Application (2013-2018)
12.3.1 Italy Alzheimer’s Disease Drug Sales by Application (2013-2018)
12.3.2 Italy Alzheimer’s Disease Drug Sales Market Share by Application (2013-2018)
12.4 Italy Alzheimer’s Disease Drug Sales, Revenue and Market Share by Manufacturer (2016-2017)
12.4.1 Italy Alzheimer’s Disease Drug Sales and Market Share by Manufacturer (2016-2017)
12.4.2 Italy Alzheimer’s Disease Drug Revenue and Market Share by Manufacturer (2016-2017)
12.5 Italy Alzheimer’s Disease Drug Export and Import (2013-2018)
13 SPAIN ALZHEIMER’S DISEASE DRUG SALES, REVENUE, BY TYPE, APPLICATION AND MANUFACTURERS
13.1 Spain Alzheimer’s Disease Drug Revenue, Sales and Growth Rate (2013-2018)
13.2 Spain Alzheimer’s Disease Drug Sales and Market Share by Type (2013-2018)
13.2.1 Spain Alzheimer’s Disease Drug Sales by Type (2013-2018)
13.2.2 Spain Alzheimer’s Disease Drug Sales Market Share by Type (2013-2018)
13.3 Spain Alzheimer’s Disease Drug Sales by Application (2013-2018)
13.3.1 Spain Alzheimer’s Disease Drug Sales by Application (2013-2018)
13.3.2 Spain Alzheimer’s Disease Drug Sales Market Share by Application (2013-2018)
13.4 Spain Alzheimer’s Disease Drug Sales, Revenue and Market Share by Manufacturer (2016-2017)
13.4.1 Spain Alzheimer’s Disease Drug Sales and Market Share by Manufacturer (2016-2017)
13.4.2 Spain Alzheimer’s Disease Drug Revenue and Market Share by Manufacturer (2016-2017)
13.5 Spain Alzheimer’s Disease Drug Export and Import (2013-2018)
14 ALZHEIMER’S DISEASE DRUG MARKET FORECAST (2018-2023)
14.1 North America and Europe Alzheimer’s Disease Drug Sales, Revenue and Growth Rate (2018-2023)
14.2 Alzheimer’s Disease Drug Market Forecast by Countries/Regions (2018-2023)
14.2.1 United States Alzheimer’s Disease Drug Sales and Growth Rate Forecast (2018-2023)
14.2.2 United Kingdom Alzheimer’s Disease Drug Sales and Growth Rate Forecast (2018-2023)
14.2.3 Canada Alzheimer’s Disease Drug Sales and Growth Rate Forecast (2018-2023)
14.2.4 Germany Alzheimer’s Disease Drug Sales and Growth Rate Forecast (2018-2023)
14.2.5 France Alzheimer’s Disease Drug Sales and Growth Rate Forecast (2018-2023)
14.2.6 Italy Alzheimer’s Disease Drug Sales and Growth Rate Forecast (2018-2023)
14.2.7 Spain Alzheimer’s Disease Drug Sales and Growth Rate Forecast (2018-2023)
14.3 Alzheimer’s Disease Drug Market Forecast by Type (2018-2023)
14.3.1 North America and Europe Alzheimer’s Disease Drug Sales Forecast by Type (2018-2023)
14.3.2 North America and Europe Alzheimer’s Disease Drug Market Share Forecast by Type (2018-2023)
14.4 Alzheimer’s Disease Drug Market Forecast by Application (2018-2023)
14.4.1 North America and Europe Alzheimer’s Disease Drug Sales Forecast by Application (2018-2023)
14.4.2 North America and Europe Alzheimer’s Disease Drug Market Share Forecast by Application (2018-2023)
15 ALZHEIMER’S DISEASE DRUG MANUFACTURING COST ANALYSIS
15.1 Alzheimer’s Disease Drug Key Raw Materials Analysis
15.1.1 Key Raw Materials
15.1.2 Price Trend of Key Raw Materials
15.1.3 Key Suppliers of Raw Materials
15.1.4 Market Concentration Rate of Raw Materials
15.2 Proportion of Manufacturing Cost Structure
15.2.1 Raw Materials
15.2.2 Labor Cost
15.2.3 Manufacturing Expenses
15.3 Manufacturing Process Analysis of Alzheimer’s Disease Drug
16 INDUSTRIAL CHAIN, SOURCING STRATEGY AND DOWNSTREAM BUYERS
16.1 Alzheimer’s Disease Drug Industrial Chain Analysis
16.2 Upstream Raw Materials Sourcing
16.3 Raw Materials Sources of Alzheimer’s Disease Drug Major Manufacturers in 2017
16.4 Downstream Buyers
17 SALES CHANNEL, DISTRIBUTORS, TRADERS AND DEALERS
17.1 Sales Channel
17.1.1 Direct Marketing
17.1.2 Indirect Marketing
17.1.3 Marketing Channel Future Trend
17.2 Distributors, Traders and Dealers
18 RESEARCH FINDINGS AND CONCLUSION
19 APPENDIX
19.1 Methodology
19.2 Data Source
1.1 Alzheimer’s Disease Drug Introduction
1.2 Market Analysis by Type
1.2.1 Donepezil
1.2.2 Memantine
1.2.3 Rivastigmine
1.3 Market Analysis by Applications
1.3.1 Early to Moderate Stages
1.3.2 Moderate to Severe Stages
1.4 Market Analysis by Countries
1.4.1 United States Status and Prospect (2013-2023)
1.4.2 Canada Status and Prospect (2013-2023)
1.4.3 United Kingdom Status and Prospect (2013-2023)
1.4.4 Germany Status and Prospect (2013-2023)
1.4.5 France Status and Prospect (2013-2023)
1.4.6 Italy Status and Prospect (2013-2023)
1.4.7 Spain Status and Prospect (2013-2023)
1.5 Market Dynamics
1.5.1 Market Opportunities
1.5.2 Market Risk
1.5.3 Market Driving Force
2 MANUFACTURERS PROFILES
2.1 Allergan
2.1.1 Business Overview
2.1.2 Alzheimer’s Disease Drug Type and Applications
2.1.2.1 Type
2.1.2.2 Type
2.1.3 Allergan Alzheimer’s Disease Drug Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.2 Eisai
2.2.1 Business Overview
2.2.2 Alzheimer’s Disease Drug Type and Applications
2.2.2.1 Type
2.2.2.2 Type
2.2.3 Eisai Alzheimer’s Disease Drug Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.3 Novartis
2.3.1 Business Overview
2.3.2 Alzheimer’s Disease Drug Type and Applications
2.3.2.1 Type
2.3.2.2 Type
2.3.3 Novartis Alzheimer’s Disease Drug Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.4 Daiichi Sankyo
2.4.1 Business Overview
2.4.2 Alzheimer’s Disease Drug Type and Applications
2.4.2.1 Type
2.4.2.2 Type
2.4.3 Daiichi Sankyo Alzheimer’s Disease Drug Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.5 Merz Pharma
2.5.1 Business Overview
2.5.2 Alzheimer’s Disease Drug Type and Applications
2.5.2.1 Type
2.5.2.2 Type
2.5.3 Merz Pharma Alzheimer’s Disease Drug Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.6 Pfizer
2.6.1 Business Overview
2.6.2 Alzheimer’s Disease Drug Type and Applications
2.6.2.1 Type
2.6.2.2 Type
2.6.3 Pfizer Alzheimer’s Disease Drug Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.7 Johnson & Johnson
2.7.1 Business Overview
2.7.2 Alzheimer’s Disease Drug Type and Applications
2.7.2.1 Type
2.7.2.2 Type
2.7.3 Johnson & Johnson Alzheimer’s Disease Drug Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.8 Lundbeck.
2.8.1 Business Overview
2.8.2 Alzheimer’s Disease Drug Type and Applications
2.8.2.1 Type
2.8.2.2 Type
2.8.3 Lundbeck. Alzheimer’s Disease Drug Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
3 NORTH AMERICA AND EUROPE ALZHEIMER’S DISEASE DRUG MARKET COMPETITION, BY MANUFACTURER
3.1 North America and Europe Alzheimer’s Disease Drug Sales and Market Share by Manufacturer (2016-2017)
3.2 North America and Europe Alzheimer’s Disease Drug Revenue and Market Share by Manufacturer (2016-2017)
3.2.1 North America and Europe Alzheimer’s Disease Drug Revenue by Manufacturer (2016-2017)
3.2.2 North America and Europe Alzheimer’s Disease Drug Revenue Market Share by Manufacturer (2016-2017)
3.3 North America and Europe Alzheimer’s Disease Drug Price by Manufacturers (2016-2017)
3.4 Market Concentration Rate
3.4.1 Top 3 Alzheimer’s Disease Drug Manufacturer Market Share (2016-2017)
3.4.2 Top 5 Alzheimer’s Disease Drug Manufacturer Market Share (2016-2017)
3.5 Market Competition Trend
4 NORTH AMERICA AND EUROPE ALZHEIMER’S DISEASE DRUG MARKET ANALYSIS BY COUNTRIES/REGIONS
4.1 North America and Europe Alzheimer’s Disease Drug Sales Market Share by Countries/Regions
4.2 North America and Europe Alzheimer’s Disease Drug Sales by Countries/Regions (2013-2018)
4.2.1 North America and Europe Alzheimer’s Disease Drug Sales by Countries/Regions (2013-2018)
4.2.2 North America and Europe Alzheimer’s Disease Drug Sales Market Share by Countries (2013-2018)
4.3 North America and Europe Alzheimer’s Disease Drug Revenue (Value) by Countries (2013-2018)
4.3.1 North America and Europe Alzheimer’s Disease Drug Revenue and Growth Rate (2013-2018)
4.3.2 North America and Europe Alzheimer’s Disease Drug Revenue Market Share by Countries (2013-2018)
5 NORTH AMERICA AND EUROPE MARKET SEGMENTATION ALZHEIMER’S DISEASE DRUG BY TYPE
5.1 North America and Europe Alzheimer’s Disease Drug Sales, Revenue and Market Share by Type (2013-2018)
5.1.1 North America and Europe Alzheimer’s Disease Drug Sales and Market Share by Type (2013-2018)
5.1.2 North America and Europe Alzheimer’s Disease Drug Revenue and Market Share by Type (2013-2018)
5.2 Donepezil Sales Growth and Price
5.2.1 North America and Europe Donepezil Sales Growth (2013-2018)
5.2.2 North America and Europe Donepezil Price (2013-2018)
5.3 Memantine Sales Growth and Price
5.3.1 North America and Europe Memantine Sales Growth (2013-2018)
5.3.2 North America and Europe Memantine Price (2013-2018)
5.4 Rivastigmine Sales Growth and Price
5.4.1 North America and Europe Rivastigmine Sales Growth (2013-2018)
6 NORTH AMERICA AND EUROPE MARKET SEGMENTATION ALZHEIMER’S DISEASE DRUG BY APPLICATION
6.1 North America and Europe Alzheimer’s Disease Drug Sales Market Share by Application (2013-2018)
6.2 Early to Moderate Stages Sales Growth (2013-2018)
6.3 Moderate to Severe Stages Sales Growth (2013-2018)
7 UNITED STATES ALZHEIMER’S DISEASE DRUG SALES, REVENUE, BY TYPE, APPLICATION AND MANUFACTURERS
7.1 United States Alzheimer’s Disease Drug Revenue, Sales and Growth Rate (2013-2018)
7.2 United States Alzheimer’s Disease Drug Sales and Market Share by Type (2013-2018)
7.2.1 United States Alzheimer’s Disease Drug Sales by Type (2013-2018)
7.2.2 United States Alzheimer’s Disease Drug Sales Market Share by Type (2013-2018)
7.3 United States Alzheimer’s Disease Drug Sales and Market Share by Application (2013-2018)
7.3.1 United States Alzheimer’s Disease Drug Sales by Application (2013-2018)
7.3.2 United States Alzheimer’s Disease Drug Sales Market Share by Application (2013-2018)
7.4 United States Alzheimer’s Disease Drug Sales, Revenue and Market Share by Manufacturer (2016-2017)
7.4.1 United States Alzheimer’s Disease Drug Sales and Market Share by Manufacturer (2016-2017)
7.4.2 United States Alzheimer’s Disease Drug Revenue and Market Share by Manufacturer (2016-2017)
7.5 United States Alzheimer’s Disease Drug Export and Import (2013-2018)
8 UNITED KINGDOM ALZHEIMER’S DISEASE DRUG SALES, REVENUE, BY TYPE, APPLICATION AND MANUFACTURERS
8.1 United Kingdom Alzheimer’s Disease Drug Revenue, Sales and Growth Rate (2013-2018)
8.2 United Kingdom Alzheimer’s Disease Drug Sales and Market Share by Type (2016-2017)
8.2.1 United Kingdom Alzheimer’s Disease Drug Sales by Type (2013-2018)
8.2.2 United Kingdom Alzheimer’s Disease Drug Sales Market Share by Type (2013-2018)
8.3 United Kingdom Alzheimer’s Disease Drug Sales and Market Share by Application (2013-2018)
8.3.1 United Kingdom Alzheimer’s Disease Drug Sales by Application (2013-2018)
8.3.2 United Kingdom Alzheimer’s Disease Drug Sales Market Share by Application (2013-2018)
8.4 United Kingdom Alzheimer’s Disease Drug Sales, Revenue and Market Share by Manufacturer (2016-2017)
8.4.1 United Kingdom Alzheimer’s Disease Drug Sales and Market Share by Manufacturer (2016-2017)
8.4.2 United Kingdom Alzheimer’s Disease Drug Revenue and Market Share by Manufacturer (2016-2017)
8.5 United Kingdom Alzheimer’s Disease Drug Export and Import (2013-2018)
9 CANADA ALZHEIMER’S DISEASE DRUG SALES, REVENUE, BY TYPE, APPLICATION AND MANUFACTURERS
9.1 Canada Alzheimer’s Disease Drug Revenue, Sales and Growth Rate (2013-2018)
9.2 Canada Alzheimer’s Disease Drug Sales and Market Share by Type (2013-2018)
9.2.1 Canada Alzheimer’s Disease Drug Sales by Type (2013-2018)
9.2.2 Canada Alzheimer’s Disease Drug Sales Market Share by Type (2013-2018)
9.3 Canada "&Sheet1!$B$1&" Sales and Market Share by Application (2013-2018)"
9.3.1 Canada Alzheimer’s Disease Drug Sales by Application (2013-2018)
9.3.2 Canada Alzheimer’s Disease Drug Sales Market Share by Application (2013-2018)
9.4 Canada Alzheimer’s Disease Drug Sales, Revenue and Market Share by Manufacturer (2016-2017)
9.4.1 Canada Alzheimer’s Disease Drug Sales and Market Share by Manufacturer (2016-2017)
9.4.2 Canada Alzheimer’s Disease Drug Revenue and Market Share by Manufacturer (2016-2017)
9.5 Canada Alzheimer’s Disease Drug Export and Import (2013-2018)
10 GERMANY ALZHEIMER’S DISEASE DRUG SALES, REVENUE, BY TYPE, APPLICATION AND MANUFACTURERS
10.1 Germany Alzheimer’s Disease Drug Revenue, Sales and Growth Rate (2013-2018)
10.2 Germany Alzheimer’s Disease Drug Sales and Market Share by Type (2013-2018)
10.2.1 Germany Alzheimer’s Disease Drug Sales by Type (2013-2018)
10.2.2 Germany Alzheimer’s Disease Drug Sales Market Share by Type (2013-2018)
10.3 Germany Alzheimer’s Disease Drug Sales and Market Share by Application (2013-2018)
10.3.1 Germany Alzheimer’s Disease Drug Sales by Application (2013-2018)
10.3.2 Germany Alzheimer’s Disease Drug Sales Market Share by Application (2013-2018)
10.4 Germany Alzheimer’s Disease Drug Sales, Revenue and Market Share by Manufacturer (2016-2017)
10.4.1 Germany Alzheimer’s Disease Drug Sales and Market Share by Manufacturer (2016-2017)
10.4.2 Germany Alzheimer’s Disease Drug Revenue and Market Share by Manufacturer (2016-2017)
10.5 Germany Alzheimer’s Disease Drug Export and Import (2013-2018)
11 FRANCE ALZHEIMER’S DISEASE DRUG SALES, REVENUE, BY TYPE, APPLICATION AND MANUFACTURERS
11.1 France Alzheimer’s Disease Drug Revenue, Sales and Growth Rate (2013-2018)
11.2 France Alzheimer’s Disease Drug Sales and Market Share by Type (2013-2018)
11.2.1 France Alzheimer’s Disease Drug Sales by Type (2013-2018)
11.2.2 France Alzheimer’s Disease Drug Sales Market Share by Type (2013-2018)
11.3 France "&Sheet1!$B$1&" Sales by Application (2013-2018)"
11.3.1 France Alzheimer’s Disease Drug Sales by Application (2013-2018)
11.3.2 France Alzheimer’s Disease Drug Sales Market Share by Application (2013-2018)
11.4 France Alzheimer’s Disease Drug Sales, Revenue and Market Share by Manufacturer (2016-2017)
11.4.1 France Alzheimer’s Disease Drug Sales and Market Share by Manufacturer (2016-2017)
11.4.2 France Alzheimer’s Disease Drug Revenue and Market Share by Manufacturer
11.5 France Alzheimer’s Disease Drug Export and Import (2013-2018)
12 ITALY ALZHEIMER’S DISEASE DRUG SALES, REVENUE, BY TYPE, APPLICATION AND MANUFACTURERS
12.1 Italy Alzheimer’s Disease Drug Revenue, Sales and Growth Rate (2013-2018)
12.2 Italy Alzheimer’s Disease Drug Sales and Market Share by Type (2013-2018)
12.2.1 Italy Alzheimer’s Disease Drug Sales by Type (2013-2018)
12.2.2 Italy Alzheimer’s Disease Drug Sales Market Share by Type (2013-2018)
12.3 Italy Alzheimer’s Disease Drug Sales and Market Share by Application (2013-2018)
12.3.1 Italy Alzheimer’s Disease Drug Sales by Application (2013-2018)
12.3.2 Italy Alzheimer’s Disease Drug Sales Market Share by Application (2013-2018)
12.4 Italy Alzheimer’s Disease Drug Sales, Revenue and Market Share by Manufacturer (2016-2017)
12.4.1 Italy Alzheimer’s Disease Drug Sales and Market Share by Manufacturer (2016-2017)
12.4.2 Italy Alzheimer’s Disease Drug Revenue and Market Share by Manufacturer (2016-2017)
12.5 Italy Alzheimer’s Disease Drug Export and Import (2013-2018)
13 SPAIN ALZHEIMER’S DISEASE DRUG SALES, REVENUE, BY TYPE, APPLICATION AND MANUFACTURERS
13.1 Spain Alzheimer’s Disease Drug Revenue, Sales and Growth Rate (2013-2018)
13.2 Spain Alzheimer’s Disease Drug Sales and Market Share by Type (2013-2018)
13.2.1 Spain Alzheimer’s Disease Drug Sales by Type (2013-2018)
13.2.2 Spain Alzheimer’s Disease Drug Sales Market Share by Type (2013-2018)
13.3 Spain Alzheimer’s Disease Drug Sales by Application (2013-2018)
13.3.1 Spain Alzheimer’s Disease Drug Sales by Application (2013-2018)
13.3.2 Spain Alzheimer’s Disease Drug Sales Market Share by Application (2013-2018)
13.4 Spain Alzheimer’s Disease Drug Sales, Revenue and Market Share by Manufacturer (2016-2017)
13.4.1 Spain Alzheimer’s Disease Drug Sales and Market Share by Manufacturer (2016-2017)
13.4.2 Spain Alzheimer’s Disease Drug Revenue and Market Share by Manufacturer (2016-2017)
13.5 Spain Alzheimer’s Disease Drug Export and Import (2013-2018)
14 ALZHEIMER’S DISEASE DRUG MARKET FORECAST (2018-2023)
14.1 North America and Europe Alzheimer’s Disease Drug Sales, Revenue and Growth Rate (2018-2023)
14.2 Alzheimer’s Disease Drug Market Forecast by Countries/Regions (2018-2023)
14.2.1 United States Alzheimer’s Disease Drug Sales and Growth Rate Forecast (2018-2023)
14.2.2 United Kingdom Alzheimer’s Disease Drug Sales and Growth Rate Forecast (2018-2023)
14.2.3 Canada Alzheimer’s Disease Drug Sales and Growth Rate Forecast (2018-2023)
14.2.4 Germany Alzheimer’s Disease Drug Sales and Growth Rate Forecast (2018-2023)
14.2.5 France Alzheimer’s Disease Drug Sales and Growth Rate Forecast (2018-2023)
14.2.6 Italy Alzheimer’s Disease Drug Sales and Growth Rate Forecast (2018-2023)
14.2.7 Spain Alzheimer’s Disease Drug Sales and Growth Rate Forecast (2018-2023)
14.3 Alzheimer’s Disease Drug Market Forecast by Type (2018-2023)
14.3.1 North America and Europe Alzheimer’s Disease Drug Sales Forecast by Type (2018-2023)
14.3.2 North America and Europe Alzheimer’s Disease Drug Market Share Forecast by Type (2018-2023)
14.4 Alzheimer’s Disease Drug Market Forecast by Application (2018-2023)
14.4.1 North America and Europe Alzheimer’s Disease Drug Sales Forecast by Application (2018-2023)
14.4.2 North America and Europe Alzheimer’s Disease Drug Market Share Forecast by Application (2018-2023)
15 ALZHEIMER’S DISEASE DRUG MANUFACTURING COST ANALYSIS
15.1 Alzheimer’s Disease Drug Key Raw Materials Analysis
15.1.1 Key Raw Materials
15.1.2 Price Trend of Key Raw Materials
15.1.3 Key Suppliers of Raw Materials
15.1.4 Market Concentration Rate of Raw Materials
15.2 Proportion of Manufacturing Cost Structure
15.2.1 Raw Materials
15.2.2 Labor Cost
15.2.3 Manufacturing Expenses
15.3 Manufacturing Process Analysis of Alzheimer’s Disease Drug
16 INDUSTRIAL CHAIN, SOURCING STRATEGY AND DOWNSTREAM BUYERS
16.1 Alzheimer’s Disease Drug Industrial Chain Analysis
16.2 Upstream Raw Materials Sourcing
16.3 Raw Materials Sources of Alzheimer’s Disease Drug Major Manufacturers in 2017
16.4 Downstream Buyers
17 SALES CHANNEL, DISTRIBUTORS, TRADERS AND DEALERS
17.1 Sales Channel
17.1.1 Direct Marketing
17.1.2 Indirect Marketing
17.1.3 Marketing Channel Future Trend
17.2 Distributors, Traders and Dealers
18 RESEARCH FINDINGS AND CONCLUSION
19 APPENDIX
19.1 Methodology
19.2 Data Source
LIST OF TABLES AND FIGURES
Figure Alzheimer’s Disease Drug Picture
Table Product Specifications of Alzheimer’s Disease Drug
Figure North America and Europe Sales Market Share of Alzheimer’s Disease Drug by Types in 2017
Ta
Figure Alzheimer’s Disease Drug Picture
Table Product Specifications of Alzheimer’s Disease Drug
Figure North America and Europe Sales Market Share of Alzheimer’s Disease Drug by Types in 2017
Ta